{"id":"dpt-ipv-hib","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL186427","moleculeType":"Small molecule","molecularWeight":"275.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This pentavalent vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens, inactivated poliovirus antigens, and Haemophilus influenzae type b conjugate antigen. Each component stimulates the immune system to produce antibodies and cellular immunity against these five pathogens, providing protection against the corresponding infectious diseases.","oneSentence":"DPT-IPV-Hib is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b through inactivated pathogen antigens and toxoids.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:56.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children"}]},"trialDetails":[{"nctId":"NCT02140047","phase":"PHASE2","title":"Exploratory Clinical Study of MT-2301","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-04","conditions":"Haemophilus Influenza Type b","enrollment":154},{"nctId":"NCT02992925","phase":"PHASE3","title":"Phase 3 Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2016-11","conditions":"Immunization; Infection","enrollment":370},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT03188692","phase":"PHASE3","title":"Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-06-23","conditions":"Immunization","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BK1310"],"phase":"phase_3","status":"active","brandName":"DPT-IPV-Hib","genericName":"DPT-IPV-Hib","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"DPT-IPV-Hib is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b through inactivated pathogen antigens and toxoids. Used for Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}